Title |
Long‐term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
|
---|---|
Published in |
Alimentary Pharmacology & Therapeutics, December 2016
|
DOI | 10.1111/apt.13893 |
Pubmed ID | |
Authors |
L. Angelison, S. Almer, A. Eriksson, P. Karling, U. Fagerberg, J. Halfvarson, M. Thörn, J. Björk, U. Hindorf, R. Löfberg, A. Bajor, H. Hjortswang, P. Hammarlund, O. Grip, J. Torp, J. Marsal, E. Hertervig, the Swedish Organization for the Study of Inflammatory Bowel diseases |
Abstract |
Real-life long-term data on infliximab treatment in ulcerative colitis are limited. To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined. A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant. Steroid-free clinical remission was achieved by 123/250 patients (49.2%) at 12 months and in 126/250 patients at a median follow-up of 2.9 years (50.4%). Primary response at 3 months was achieved by 190/250 (76.0%) patients and associated with a high probability of response 168/190 (88.4%) at 12 months and 143/190 (75.3%) at follow-up. Long-term rate of colectomy in primary responders was 6/190 (3.2%) at 12 months and 27/190 (14.2%) at last follow-up. Failure to achieve response at 3 months was associated with a high risk of subsequent colectomy, 29/60 (48.3%) at 12 months and 41/60 (68.3%) at follow-up. Response at 12 months was associated with a low risk of subsequent colectomy, 14/181 (7.7%) compared with non-response 19/34 (55.9%) (P < 0.0001). Non-response at 3 months was an independent predictor of subsequent colectomy (HR = 9.40, 95% CI = 5.10-17.35, P < 0.001). Concomitant azathioprine therapy did not influence outcome in terms of colectomy. Long-term efficacy of infliximab treatment in chronic active ulcerative colitis is excellent especially in patients who respond to induction treatment. Conversely, non-response at 3 months predicts a poor outcome, with a high risk of subsequent colectomy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 50% |
Brazil | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 81 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 10 | 12% |
Student > Master | 10 | 12% |
Researcher | 9 | 11% |
Other | 6 | 7% |
Student > Bachelor | 5 | 6% |
Other | 19 | 23% |
Unknown | 22 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 49% |
Nursing and Health Professions | 3 | 4% |
Agricultural and Biological Sciences | 3 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Computer Science | 2 | 2% |
Other | 6 | 7% |
Unknown | 25 | 31% |